Home > Journals > Minerva Medica > Past Issues > Articles online first > Minerva Medica 2016 Nov 25





A Journal on Internal Medicine

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236



Minerva Medica 2016 Nov 25

language: English

Alghedon fentanyl transdermal system (AFTS)

Patrizia ROMUALDI 1, Patrizia SANTI 2, Sanzio CANDELETTI 1

1 Department of Pharmacy and Biotechnology, Alma Mater Studiorum­, University of Bologna, Bologna, Italy; 2 Department of Pharmacy, University of Parma, Parma, Italy


The efficacy of transdermal fentanyl for cancer pain and chronic non­cancer pain (chronic lower back pain, rheumatoid arthritis, osteoarthritis, neuropathic pain) is well established. Several formulations of fentanyl transdermal systems have been developed to improve the drug delivery and prevent misuse of the active principle. The addition of a rate controlling membrane to the matrix system represented an important advance. The design and functional features of Alghedon patch are compared with other approved generic fentanyl transdermal systems, emphasizing the distinctiveness of Alghedon patch. Alghedon patch has no liquid component in the finished product and, therefore, no leakage of active ingredient from the system can occur. A rate­controlling membrane provides controlled release of the active substance from the matrix reservoir, ensuring that fentanyl delivery and entry into the microcirculation is not solely controlled by the skin’s permeability to this active substance. Alghedon patch contains part of the drug (approx. 15%) in the skin contacting adhesive: this innovative solution allows to overcome a typical drawback of transdermal patches, i.e. the long lag­time before the drug appears in plasma after the first administration, and provides rapid analgesia during the first hours of administration. Alghedon Fentanyl Transdermal System employs materials commonly used in other transdermal applications and having established safety profiles. For each strength, the fentanyl content and, thus, the resulting residual fentanyl remaining in the patch after use, is at the lowest end of the range used in commercial fentanyl patches, minimizing the potential for abuse and misuse.

top of page

Publication History

Cite this article as

Corresponding author e-mail